Scientific Publications

Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques

Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.

Sci Rep. 2017 Jun 23;7(1):4122

Read more

Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes

Mann JF, McKay PF, Fiserova A, Klein K, Cope A, Rogers P, Swales J, Seaman MS, Combadiere B, Shattock RJ.

J Virol. 2014 Jun;88(12):6959-69

Read more

Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.

Vardas E, Stanescu I, Leinonen M, Ellefsen K, Pantaleo G, Valtavaara M, Ustav M, Reijonen K.
Vaccine. 2012 Apr 28.
Read more

Immunization with dendritic cells transfected in vivo with HIV-1 plasmid DNA induces HIV-1-specific immune responses.

Malm M, Krohn K, Blazevic V.

Arch Virol. 2011 Sep;156(9):1607-10

Read more

Effective Formation of the Segregation-Competent Complex Determines Successful Partitioning of the Bovine Papillomavirus Genome during Cell Division.

Silla T, Männik A, Ustav M.

J Virol. 2010 Nov; 84(21): 11175–11188

Read more

Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV-Study in domestic pigs

Mölder T, Adojaan M, Kaldma K, Ustav M, Sikut R.
Vaccine. 2009 Oct 28.
Read more

Persistent Immune Responses Induced by a Human Immunodeficiency Virus DNA Vaccine Delivered in Association with Electroporation in the Skin of Nonhuman Primates

Martinon F, Kaldma K, Sikut R, Culina S, Romain G, Tuomela M, Adojaan M, Männik A, Toots U, Kivisild T, Morin J, Brochard P, Delache B, Tripiciano A, Ensoli F, Stanescu I, Le Grand R, Ustav M.
Hum Gene Ther. 2009 Oct 5.
Read more

Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses

Bråve A, Hallengärd D, Malm M, Blazevic V, Rollman E, Stanescu I, Krohn K.
Vaccine. 2009 Jan 7;27(2):184-6. Epub 2008 Nov 4.
Read more

GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model

Malm M, Sikut R, Krohn K, Blazevic V.
Vaccine. 2007 Apr 30;25(17):3293-301.
Read more

High prevalence of the CCR5Delta32 HIV-resistance mutation among Estonian HIV type 1-infected individuals

Adojaan M, Mölder T, Männik A, Kivisild T, Villems R, Krispin T, Ustav M.
AIDS Res Hum Retroviruses. 2007 Feb;23(2):193-7.
Read more

Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine

Blazevic V, Männik A, Malm M, Sikut R, Valtavaara M, Toots U, Ustav M, Krohn K.
AIDS Res Hum Retroviruses. 2006 Jul;22(7):667-77.
Read more

Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH

Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, Blazevic V.
Viral Immunol. 2005;18(4):678-88.
Read more

A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies

Krohn K, Stanescu I, Blazevic V, Vesikari T, Ranki A, Ustav M.
Microbes Infect. 2005 Nov;7(14):1405-13. Epub 2005 Oct 4.
Read more

Validation overview of bio-analytical methods

Tuomela M, Stanescu I, Krohn K.
Gene Ther. 2005 Oct;12 Suppl 1:S131-8. Review.
Read more

Predominance of a rare type of HIV-1 in Estonia

Adojaan M, Kivisild T, Männik A, Krispin T, Ustina V, Zilmer K, Liebert E, Jaroslavtsev N, Priimägi L, Tefanova V, Schmidt J, Krohn K, Villems R, Salminen M, Ustav M.
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):598-605.
Read more

Biodistribution and general safety of a naked DNA plasmid, GTU-MultiHIV, in a rat, using a quantitative PCR method

Tuomela M, Malm M, Wallen M, Stanescu I, Krohn K, Peterson P.
Vaccine. 2005 Jan 4;23(7):890-6.
Read more